BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 7649498)

  • 1. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.
    Diener HC; Föh M; Iaccarino C; Wessely P; Isler H; Strenge H; Fischer M; Wedekind W; Taneri Z
    Cephalalgia; 1996 Oct; 16(6):441-7. PubMed ID: 8902255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
    Mastrosimone F; Iaccarino C; de Caterina G
    J Med; 1992; 23(1):1-16. PubMed ID: 1573338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
    Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
    Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beta-blockers and migraine. Efficacy of time-release propranolol versus placebo].
    Pradalier A; Serratrice G; Collard M; Hirsch E; Feve J; Masson M; Masson C; Dry J; Koulikovsky G; Nguyen G
    Therapie; 1990; 45(5):441-5. PubMed ID: 2260046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis.
    Rao BS; Das DG; Taraknath VR; Sarma Y
    Neurol India; 2000 Sep; 48(3):223-6. PubMed ID: 11025624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine].
    Maissen CP; Ludin HP
    Schweiz Med Wochenschr; 1991 Oct; 121(43):1585-90. PubMed ID: 1947955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
    Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
    Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study.
    Honkaniemi J; Liimatainen S; Rainesalo S; Sulavuori S
    Headache; 2006 May; 46(5):781-7. PubMed ID: 16643581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P; Rothner AD; Wooten JD; Webster C; Ames M
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
    Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
    Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
    Kudrow D; Thomas HM; Ruoff G; Ishkanian G; Sands G; Le VH; Brown MT
    Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.
    Nappi G; Sandrini G; Savoini G; Cavallini A; de Rysky C; Micieli G
    Drugs; 1987; 33 Suppl 2():103-9. PubMed ID: 3304950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.